Morris Sherman, MD, PhD, professor of Medicine at University of Toronto, discusses the emergence of regorafenib (Stivarga) and how it fits into the treatment of hepatocellular carcinoma (HCC).
Morris Sherman, MD
Advertisement
Articles by Morris Sherman, MD
Advertisement
Latest Updated Articles
Dr. Sherman on the Role of Regorafenib in Liver CancerJanuary 13th 2017
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Zanidatamab-Based Regimens for First-Line HER2+ Locally Advanced or Metastatic Gastric Cancer
2
FDA Grants Fast Track Designation to Pan-RAS Molecular Glue ERAS-0015 for Metastatic Pancreatic Adenocarcinoma
3
FDA Grants Priority Review to Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
4
MOMENTUM Trial Aims to Add Further Evidence for Cemsidomide in R/R Myeloma
5